U
CORT icon

UBS’s Corcept Therapeutics CORT Stock Holding History

UBS’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$359K Sell
134,131
-21,000
-14% -$55.6K ﹤0.01% 4598
2014
Q2 		$434K Sell
155,131
-5,000
-3% -$14.8K ﹤0.01% 4359
2014
Q1 		$698K Sell
160,131
-4,151
-3% -$14.5K ﹤0.01% 3883
2013
Q4 		$527K Buy
164,282
+1,440
+0.9% +$2.91K ﹤0.01% 4272
2013
Q3 		$259K Sell
162,842
-45,712
-22% -$80.6K ﹤0.01% 4863
2013
Q2 		$361K Buy
+208,554
New +$375K ﹤0.01% 4442

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $6.03B AUM 24.5% 1-Year Est. Return

UBS's CORT Position: Q3 2014 in Review

UBS reduced its Corcept Therapeutics (CORT) stake by 14% in Q3 2014, selling an estimated $55.6K and leaving 134,131 shares worth $359K. The position accounts for ﹤0.01% of the portfolio, ranked #4598.

UBS first reported a position in CORT in Q2 2013 and has held it in 6 quarters since. The position peaked at $698K in Q1 2014. 55 funds tracked by Wall St. Rank hold CORT as of Q3 2014.

  • UBS held 134,131 shares of Corcept Therapeutics worth $359K as of Q3 2014.
  • UBS sold 21,000 Corcept Therapeutics shares in Q3 2014, an estimated $55.6K.
  • Corcept Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4598 holding.
  • UBS first reported a position in Corcept Therapeutics in Q2 2013 and has held it in 6 quarters since.
  • UBS's Corcept Therapeutics position peaked at $698K in Q1 2014.
  • 55 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.